CANOVA
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- NCT03539744 ↗
- Active, not recruiting
- AbbVie
- Deep
We haven't built an HCP commentary report on CANOVA (venetoclax, pomalidomide and 1 more in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CANOVA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 73 | |
| YouTube | 27 | |
| Podcasts | 17 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide; Dexamethasone; Venetoclax
- Arms
- Arm 1 VenDex · Experimental
- Arm 2 PomDex · Active comparator
- Enrollment
- 265
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- AbbVie with Roche-Genentech
- Start
- Oct 22, 2018
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03539744 · updated Jun 19, 2025
Publications
linked from the registry- Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortum KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2026 Jan 20;44(3):164-175. doi: 10.1200/JCO-25-00924. Epub 2025 Dec 10. PubMed 41370738